Related Experiment Videos
Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation
J J Li1, C Westergaard, P Ghosh
1Laboratory of Biochemical Physiology, National Cancer Institute, Frederick Cancer Research and Development Center, NIH, Maryland 21702, USA. lij@ncifcrf.gov
Abstract:
Cross-coupling of active protein-1 (AP-1) and nuclear factor (NF)-kappaB has been reported. In the present study, we investigated the possibility that both of these two transcription factors might contribute to the process of tumor promoter-induced transformation. To establish a stable reporter cell system, two reporter genes were stably transfected into a JB6 mouse tumor promotion-sensitive (P+) cell line: a luciferase reporter controlled by a collagenase AP-1 sequence and a chloramphenicol acetyltransferase reporter controlled by an interleukin 6 NF-kappaB sequence. This double-reporter cell line maintained the phenotype of tumor promotion sensitivity and was able to report basal or induced AP-1 and NF-kappaB transactivation. The cytokine tumor promoter tumor necrosis factor (TNF)-alpha transactivated NF-kappaB and AP-1 for both DNA binding and transcriptional activity. Pyrrolidine dithiocarbamate, an antioxidant that acts as an NF-kappaB inhibitor, efficiently inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA) or TNF-alpha induced NF-kappaB as well as AP-1 transactivation and cell transformation, suggesting dependency of transformation on both transcription factors. The AP-1 transrepressing-retinoid SR11302 transrepressed AP-1 and cell transformation when these were TPA induced but not when TNF-alpha induced, indicating different signaling pathways for TNF-alpha and TPA. Supershift electrophoresis mobility shift assay revealed that Jun B and c-Jun were absent from the AP-1/DNA complex following TNF-alpha but present following TPA treatment. Together, these results suggest that both AP-1 and NF-kappaB activation may be required for transformation whether induced by TPA or by TNF, and the differential sensitivity of TPA and TNF-alpha-induced transformation to inhibition by a retinoid might be explained by differences in the composition of the DNA-bound AP-1 complexes.
Insights
This study shows that both AP-1 and NF-kappaB transcription factors are crucial for tumor promoter-induced cell transformation. Inhibiting these factors or altering AP-1 complex composition affects transformation, revealing distinct signaling pathways for different tumor promoters.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Cross-coupling between Activator Protein-1 (AP-1) and Nuclear Factor-kappaB (NF-kappaB) has been previously observed.
- The specific roles of these transcription factors in tumor promoter-induced cell transformation require further investigation.
Purpose of the Study:
- To investigate the contribution of AP-1 and NF-kappaB to tumor promoter-induced cell transformation.
- To establish a reporter cell system for simultaneous monitoring of AP-1 and NF-kappaB activity.
Main Methods:
- Development of a double-reporter cell line (JB6 P+ cells) with luciferase and CAT reporters for AP-1 and NF-kappaB, respectively.
- Treatment with tumor necrosis factor-alpha (TNF-alpha), 12-O-tetradecanoylphorbol-13-acetate (TPA), pyrrolidine dithiocarbamate (PDTC), and retinoid SR11302.
- Analysis of DNA binding and transcriptional activity using supershift electrophoresis mobility shift assay.
Main Results:
- TNF-alpha and TPA induced both NF-kappaB and AP-1 transactivation.
- PDTC inhibited TPA- or TNF-alpha-induced NF-kappaB, AP-1 transactivation, and cell transformation.
- SR11302 inhibited TPA-induced AP-1 and cell transformation, but not TNF-alpha-induced transformation.
- Supershift assay revealed differences in AP-1 complex composition (Jun B, c-Jun) between TPA and TNF-alpha treatments.
Conclusions:
- Both AP-1 and NF-kappaB activation are necessary for cell transformation induced by TPA or TNF-alpha.
- Differential signaling pathways are involved in TPA and TNF-alpha-induced transformation.
- The composition of AP-1 DNA-binding complexes may explain the differential sensitivity to retinoid inhibition.